HIF1A and prostate cancer: Regarding the PI3K/Akt/mTOR pathway, the YC-1 drug has been found to inactivate this pathway by reducing the accumulation of HIF-1a and HIF-1b and antagonizing the activation of nuclear factor (NF-kB) induced by hypoxia in prostate cancer cells [97].